Study indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complications

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup